Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571519 · ClinicalTrials.gov registry record · Phase 3
Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 3
- Development phase
- 94
- Enrollment target
NCT00571519 is a Phase 3 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 94 participants.
The verdict
NCT00571519, a Phase 3 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 94 participants
- Enrollment target
Study Summary
This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in participants with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. Pioglitazone is used as active comparator. The total duration of a participant's participation will be approximately 30 weeks, including a 2-week placebo lead-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period. Participants who complete the randomized portion of the study per protocol may have the opportunity to continue in a long-term extension study of active treatments.
Interventions
- DRUG placebo
- DRUG Rivoglitazone HCl
- DRUG rivoglitazone HCl
- DRUG pioglitazone HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2007-11-14 |
| Est. Completion | 2008-05-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571519
The ClinicalTrials.gov registry entry for NCT00571519 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00571519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571519 about?
NCT00571519 is a clinical study titled "Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus". This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in participants with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. Pioglitazone is used as a...
What is the current status of trial NCT00571519?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 94 participants. The study started on 2007-11-14. Estimated completion is 2008-05-23.
What interventions are being tested in trial NCT00571519?
The interventions under investigation include: placebo (DRUG), Rivoglitazone HCl (DRUG), rivoglitazone HCl (DRUG), pioglitazone HCl (DRUG).
Who is sponsoring clinical trial NCT00571519?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.